Search:
   

Friday, December 14, 2018

Equity Corporate Actions Alert #2018 - 237
(UPDATED) Information Regarding the Merger of Endocyte, Inc. (ECYT)

Category:

  • Industry Announcement

Markets Impacted:

Contact Information:

Resources:

Shareholders of Endocyte, Inc. (ECTY) met on Thursday, December 20, 2018 and voted to approve the merger of the company with and into Novartis AG. The merger became effective today, Friday, December 21, 2018. The details are as follows:

Company: Endocyte, Inc.
Issue: Common Stock
CUSIP#: 29269A102
Symbol: ECYT
Marketplace Effective Date for Suspension: Monday, December 24, 2018
Merger Consideration: $24.00 in cash, per each share held.

Please follow Nasdaq on Facebook RSS and Twitter.

Nasdaq (Nasdaq: NDAQ) is a leading global provider of trading, clearing, exchange technology, listing, information and public company services. Through its diverse portfolio of solutions, Nasdaq enables customers to plan, optimize and execute their business vision with confidence, using proven technologies that provide transparency and insight for navigating today's global capital markets. As the creator of the world's first electronic stock market, its technology powers more than 90 marketplaces in 50 countries, and 1 in 10 of the world's securities transactions. Nasdaq is home to approximately 3,900 total listings with a market value of approximately $13 trillion. To learn more, visit: business.nasdaq.com.

View NASDAQTrader.com Mobile